Anticonvulsants News and Research

RSS

CHUM neurosurgeon raises funds for epilepsy research

On January 8, 2010, CHUM neurosurgeon Dr. Alain Bouthillier will leave for Argentina, where he will brave the 6,962-metre heights (over 22,840 feet) of Mount Aconcagua. Dr. Bouthillier's climb is intended to raise public awareness about epilepsy and raise funds for further research on the illness.

15 Dec 2009

Folate-enriched prescription medical food lowers medical costs of patients with peripheral neuropathy

Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress.

28 Oct 2009

HealthCore study shows Metanx tablets reduces health plan costs

27 Oct 2009

Physicians lack knowledge of off-label drug use and FDA approval status

In a recent national survey, a substantial minority of physicians erroneously believed that certain off-label uses of prescription drugs were approved by the Food and Drug Administration. This mistaken belief could encourage them to prescribe these drugs, despite the lack of scientific evidence supporting such use.

21 Aug 2009

Vulvodynia, the most frequent cause of painful sex

PAINFUL SEX. It's a secret that millions of women live with in embarrassment and isolation. Until now. . .

10 Aug 2009

New anticonvulsant compound prevents seizure progression in model of epilepsy

Carnegie Mellon University researchers have identified a new anticonvulsant compound that has the potential to stop the development of epilepsy. The findings are published in the March issue of the journal Epilepsia.

4 May 2009

Anti-seizure drugs may increase risk of cardiovascular problems

An important clinical repercussion in the treatment of epilepsy has been discovered by a research team led by Scott Mintzer, M.D., assistant professor in the Department of Neurology and the Jefferson Comprehensive Epilepsy Center at Jefferson Medical College of Thomas Jefferson University.

20 Mar 2009

Cooling brain prevents cell death in young mice exposed to anesthesia

New research from Washington University School of Medicine in St. Louis suggests cooling the brain may prevent the death of nerve cells that has been observed in infant mice exposed to anesthesia.

17 Nov 2008

New hope for Batten disease sufferers

Investigators at the University of Rochester Medical Center have uncovered a promising drug therapy that offers a ray of hope for children with Batten disease – a rare neurodegenerative disease that strikes seemingly healthy kids, progressively robs them of their abilities to see, reason and move, and ultimately kills them in their young twenties.

3 Jan 2008

New ray of hope for children with Batten disease

Investigators at the University of Rochester Medical Center have uncovered a promising drug therapy that offers a ray of hope for children with Batten disease

13 Dec 2007

Little evidence to support therapies for post-traumatic stress disorder

Post-traumatic stress disorder (PTSD) is a severe and ongoing emotional reaction to an extreme psychological trauma; it affects significant numbers of people, in particular military personnel and veterans, who have seen active duty in war zones.

22 Oct 2007

Review of PTSD treatments

Many people, including significant proportions of active duty military personnel and veterans, suffer from post-traumatic stress disorder (PTSD), often in conjunction with other injuries or illnesses.

19 Oct 2007

FDA approves Norditropin for short stature in children with Noonan syndrome

Novo Nordisk has announced that Norditropin (somatropin[rDNA origin] injection) received U.S. Food and Drug Administration (FDA) approval for the treatment of short stature in children with Noonan syndrome.

3 Jun 2007

Cancer patients are at high risk for potential drug interactions

Potential drug interactions from prescribed medications are common among cancer patients and may cause unnecessary harm, according to a study in the April 18 Journal of the National Cancer Institute .

18 Apr 2007

FDA approves Prezista (darunavir)

FDA approves Prezista (darunavir), a new drug for adults whose infection with the human immunodeficiency virus (HIV) has not responded to treatment with other antiretroviral drugs.

26 Jun 2006

Novel research points to promising relief target for chronic pain

By some accounts, chronic pain affects nearly 100 million Americans from such varied causes as arthritis, sciatica, cancer, diabetes. Most forms of pain result from identifiable causes which serve the "good" purpose in warning of a real physical problem that needs attention, or rest.

6 Jun 2006

Off-label prescribing common, often not backed by data

A study of office-based physicians in the United States suggests that about one-fifth of medications are prescribed to treat conditions for which they are not approved by the U.S. Food and Drug Administration (FDA), and that nearly three-fourths of those uses lack strong scientific support, according to an article in the May 8 issue of Archives of Internal Medicine.

9 May 2006

Large scale study shows success of epilepsy surgery

In one of the largest epilepsy surgery studies ever conducted, Mayo Clinic researchers have found that 81 percent of patients with intractable epilepsy become totally or nearly seizure-free six months following epilepsy surgery. Ten years later, 72 percent remained totally or nearly seizure-free.

11 Apr 2006

Repligen commences phase 2 trial of RG2417 for bipolar depression

Repligen Corporation today announced that the Company has initiated a Phase 2 clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

9 Mar 2006

SSRIs most effective in treating post-traumatic stress disorder

A variety of medications can help reduce the core symptoms of post-traumatic stress disorder (PTSD) as well as reduce associated depression and disability, but selective serotonin reuptake inhibitors (SSRIs) should be considered as first line agents as there is most evidence showing that these can be effective.

25 Jan 2006